No Data
Express News | Neurosense Therapeutics Ltd Files for Offering of up to 10 Mln Ordinary Shares
NeuroSense Therapeutics Secures Continued Nasdaq Listing
Neurosense, FDA to Meet Nov. 6 to Discuss Design of Amyotrophic Lateral Sclerosis Treatment Trial; Shares Rise
Express News | Neurosense Therapeutics: FDA Type C Meeting Scheduled for Nov 6 for Phase 3 ALS Trial
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
EXCLUSIVE: NeuroSense Therapeutics Tells Benzinga Co. Secures Key FDA Meeting To Advance It Phase III ALS Trial And NDA Submission
No Data
No Data